Home > Cardiology > AHA 2021 > Heart Failure > CHIEF-HF: Canagliflozin improves health status in heart failure

CHIEF-HF: Canagliflozin improves health status in heart failure

Presented By
Prof. John Spertus, University of Missouri-Kansas City, USA
Conference
AHA 2021
Trial
Phase 3, CHIEF-HF
Canagliflozin improved heart failure (HF) symptoms compared with placebo, regardless of ejection fraction or diabetes status in patients with any type of HF. Moreover, the effects were observed as early as 2 weeks from treatment initiation. The phase 3 CHIEF-HF trial was conducted without in-person visitations, which resulted in a diverse study population and a high completion rate. Prof. John Spertus (University of Missouri-Kansas City, MO, USA) explained that canagliflozin has been shown to reduce HF outcomes and improve renal protection in patients with type 2 diabetes [1]. However, the agent has not yet been approved for a primary HF indication. The randomised, double-blind, placebo-controlled, phase 3 CHIEF-HF trial (NCT04252287) assessed the efficacy of canagliflozin on symptom improvement in patients with any type of HF. Participants could register for the t...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on